EUROPEAN JOURNAL OF
PHARMACEUTICAL AND MEDICAL RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE  , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , 

 ISSN 2394-3211

Impact Factor: 6.222

 ICV - 79.57

Abstract

THE EFFICACY OF COMBINATION LEFLUNOMIDE AND METHOTREXATE (MTX) THERAPY FOR PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS

Dr. Utpal Kumar Chanda*, Dr. Pritish Tarafder, Dr. Sk. Moazem Hossain and Dr. Shailendranath Biswas

ABSTRACT

Background: Rheumatoid arthritis (RA) is a progressive inflammatory disease of unknown etiology that causes mortality. In recent days it was found that, methotrexate (MTX) combined with leflunomide (LEF) demonstrated a substantial incremental benefit in patients with RA. Objective: In the study our main aim is to evaluate the Outcome of Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis. Method: This cross sectional study was carried out at tertiary medical hospital from February 2021 to February 2022. Where a total of 200 patients of Rheumatoid Arthritis were attended OPD were included as a sample size. During the study patients were divided into two group, placebo + MTX, n=100, whereas patients randomized to LEF and MTX continued treatment [(LEF/LEF) + MTX], n=100, were used as another group. Results: During the study, majority were belonging to 45-55 years age group, 65% and 85% were male. In the patients who switched from PLA to LEF therapy while taking background MTX, the ACR20 responder-at-endpoint rate was 25.0% at Week 24, which increased to 59.4% at Week 48, and was statistically different (p < 0.0001). in addition, there was a further improvement in the mean change in HAQ DI at Week 48 (–0.33) compared with that seen at Week 24. In Placebo+MTX group events like diarrhea, nausea, gastroenteritis, vomiting, sore mouth, UTI, hypotension were higher than LEF+MTX. Conclusion: The therapeutic advantage of combination LEF + MTX for the treatment of RA in patients with active illness receiving MTX alone was maintained for 48 weeks, including improvements in signs and symptoms (ACR response), physical function (HAQ DI).

Keywords: Rheumatoid arthritis (RA), meth'otrexate (MTX), leflunomide (LEF).


[Full Text Article]

INDEXING

NEWS & UPDATION

  • New Issue Published

    Its Our pleasure to inform you that, EJPMR 1 February 2023 Issue has been Published, Kindly check it on https://www.ejpmr.com/issue

  • EJPMR: FEBRUARY ISSUE PUBLISHED

    FEBRUARY issue has been successfully launched on 1 FEBRUARY 2023.

  • EJPMR New Impact Factor

    Its our Pleasure to Inform you that EJPMR Impact Factor has been increased from  5.804 to 6.222, due to high quality Publication at International Level

  • Index Copernicus Value

    EJPMR Received Index Copernicus Value 79.57, due to High Quality Publication in EJPMR at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • Article Invited for Publication

    Article are invited for publication in EJPMR Coming Issue

Google Scholar Indian Science Publications InfoBase Index (In Process) SOCOLAR, China Research Bible, Fuchu, Tokyo. JAPAN International Society for Research activity (ISRA) Scientific Indexing Services (SIS) Polish Scholarly Bibliography Global Impact Factor (GIF) (Under Process) Universal Impact Factor International Scientific Indexing (ISI), UAE Index Copernicus CAS (A Division of American Chemical Society) USA (Under Process) Directory of Open Access Journal (DOAJ, Sweden, in process) UDLedge Science Citation Index CiteFactor Directory Of Research Journal Indexing (DRJI) Indian citation Index (ICI) Journal Index (JI, Under Process) Directory of abstract indexing for Journals (DAIJ) Open Access Journals (Under Process) Impact Factor Services For International Journals (IFSIJ) Cosmos Impact Factor Jour Informatics (Under Process) Eurasian Scientific Journal Index (ESJI) International Innovative Journal Impact Factor (IIJIF) Science Library Index, Dubai, United Arab Emirates Pubmed Database [NLM ID: 101669306] (Under Process) IP Indexing (IP Value 2.40) Web of Science Group (Under Process) Directory of Research Journals Indexing Scholar Article Journal Index (SAJI) International Scientific Indexing ( ISI ) Scope Database